What is StataDX?
StataDX is a biotechnology research firm dedicated to pioneering blood-based diagnostic technologies for neurological disorders. The company's core platform integrates sophisticated biomarker discovery with advanced assay development, aiming to provide rapid and accessible methods for detecting and monitoring brain health conditions. This approach positions StataDX at the forefront of non-invasive neurological diagnostics, a critical area for early intervention and disease management.
How much funding has StataDX raised?
StataDX has raised a total of $1.9M across 1 funding round:
Private Equity
$1.9M
Private Equity (2026): $1.9M, investors not publicly disclosed
What's next for StataDX?
With this substantial enterprise-level backing, StataDX is poised for accelerated growth and innovation. The strategic investment signals confidence from its financial partners in the company's potential to disrupt the neurological diagnostics market. Future endeavors will likely focus on expanding clinical validation, scaling manufacturing capabilities, and forging strategic partnerships to bring its diagnostic solutions to a wider patient population. The company's commitment to advancing brain health monitoring through accessible technology remains its primary objective.
See full StataDX company page
